Cardiogenetics

Why Men Die Earlier

Chromosomes

A study published in Science found that the loss of the Y chromosome, which occurs naturally in many men as they age, can cause heart scarring and premature death.

Scientists have known for half a century that the Y chromosome can disintegrate over time, but they weren’t sure if the downstream consequences mattered. 

New research from the University of Virginia suggests that the consequences of a degrading Y chromosome definitely matter. When researchers genetically removed the Y chromosome from the white blood cells of mice, they found that:

  • The mice died earlier and with more cardiac fibrosis.
  • Heart function was restored by treating the mice with a drug that blocks heart scarring. 

To tie these findings to human men, the researchers analyzed genetic data from the UK Biobank (223k men) and found that:

  • Men with a mosaic loss of the Y chromosome had a 41% increased risk of dying from any cause during a 7-year follow-up, and a 31% increased risk of dying from cardiovascular disease. 
  • These men were two to three times more likely to die of congestive heart failure or heart disease.
  • As Y chromosome loss increased, so did the risk of dying from CVD. 

A drug that may help counter the Y loss-associated heart scarring is already on the market. FDA-approved pirfenidone is used to treat idiopathic pulmonary fibrosis, a form of lung scarring, and has undergone trials for heart failure. The study’s authors note that men with Y loss may have a “superior response to this class of therapeutic agents,” although this has not been tested directly yet. 

The Takeaway

These findings demonstrate that Y chromosome loss can directly contribute to age-related heart disease through tissue scarring, and suggest that targeting the effects of Y chromosome loss could help men live longer, healthier lives. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]

This content is exclusive to subscribers

Log in or join by entering your email below.

Completely free. Every Monday and Thursday.

CW Phone Square